SQZ's innovative technology uses membrane disruption to deliver material into cells. It has demonstrated the ability to deliver a wide range of materials into numerous primary cell types with minimal impact on function and viability.
Small molecule drugs. Early generation drug developers were almost exclusively focused on developing small molecule compounds. These materials impart their therapeutic benefit by interacting with disease-related pathways in the patient at the molecular level.
Biologics. With the advent of recombinant DNA technology, scientists were able to develop a new class of protein-based therapeutics. These drugs, being biological in origin, were able to achieve functional benefits in a new range of diseases difficult to address with small molecule drugs.
Cell Therapies: As our understanding of biology continues to improve, scientists have become increasingly interested in the potential of using engineered cells as therapeutics. In contrast to small molecule drugs and biologics, which conduct simple functions at the molecular level, cell-based therapeutics have the potential to leverage a diversity of complex cellular functions to impart their clinical benefit. Early implementations of cell-based therapies have already yielded dramatic benefits for some patients.
The cell engineering challenge: limited capability means limited ability.
To date, few cell therapy concepts have been successfully applied to patients, often due to limited ability to deliver the necessary cell engineering materials to the target cell. Commercial organizations have also struggled to implement cell therapy concepts at scale due to the complexity and limitations of existing technologies.
Effective with a broad variety of cells including:
•Red blood cells
•All mammalian cells tested (to date)
Unconstrained delivery to cytosol for a variety of materials, for example:
Engineer the desired function with minimal side effects:
The transformative potential of the SQZ process is to deliver a diversity of materials (e.g., antigens, transcription factors) into a wide variety of cells (e.g., stem cells, T cells, B cells) with minimal disruption of function. As a result, our team is working to develop new therapies to transform patients’ lives.
SQZ provides unique capabilities that allow us to modulate a broader range of functions—generating novel approaches to therapy
SQZ enables robust new approaches to probing disease biology and identifying impactful targets for conventional or cellular therapy
SQZ engineers millions of cells per second regardless of cell type, material, or application